
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical Co. is poised for sustained growth, with projected sales increasing from a normalized $146 million in 2025 to $156 million in 2026, reflecting a compound annual growth rate driven by market growth and gains in ICL market share. The company is expected to benefit from the anticipated domestic launch of the EVO lens and an increase in international adoption, which positions it for above-market volume growth and significant margin improvement. Additionally, the management's focus on streamlining operations and reducing costs further strengthens the company’s potential for long-term growth in the refractive surgery market.
Bears say
Staar Surgical Co. is facing significant challenges that contribute to a negative outlook on its stock, including flat to declining revenue projections primarily due to issues in the Chinese market and elevated inventory levels impacting sales recognition. The company's recent performance reflected a disappointing $27.5 million revenue hit, which compounded existing weaknesses and raised concerns about future guidance and normalized earnings. Additionally, various risks, such as patients' affordability of out-of-pocket expenses for procedures, competitive pressures from lower-cost alternatives, and geopolitical vulnerabilities, further exacerbate the uncertainty surrounding Staar Surgical's financial health.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares